139 related articles for article (PubMed ID: 37855437)
1. Economic burden of advanced lung cancer patients treated by gefitinib alone and combined with chemotherapy in two regions of China.
Yang K; Hua S; Wei W; Yang C; Zhu X; Li SC
J Med Econ; 2023; 26(1):1424-1431. PubMed ID: 37855437
[TBL] [Abstract][Full Text] [Related]
2. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
3. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
4. [Survey of economic burden of hepatitis B-related diseases in 12 areas in China].
Ma QS; Liang S; Xiao HW; Zhang SX; Zhuang GH; Zou YH; Tan HZ; Liu JC; Zhang YH; Xu AQ; Zhang L; Feng XX; Hu DS; Wang FZ; Cui FQ; Liang XF
Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Jul; 38(7):868-876. PubMed ID: 28738457
[No Abstract] [Full Text] [Related]
5. Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
Brown T; Pilkington G; Bagust A; Boland A; Oyee J; Tudur-Smith C; Blundell M; Lai M; Martin Saborido C; Greenhalgh J; Dundar Y; Dickson R
Health Technol Assess; 2013 Jul; 17(31):1-278. PubMed ID: 23886301
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of first-line treatments for advanced epidermal growth factor receptor-mutant non-small cell lung cancer patients.
Li WQ; Li LY; Chai J; Cui JW
Cancer Med; 2021 Mar; 10(6):1964-1974. PubMed ID: 33626238
[TBL] [Abstract][Full Text] [Related]
7. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
[TBL] [Abstract][Full Text] [Related]
8. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
9. Measuring direct non-medical burden among patients with advanced non-small cell lung cancer in China: is there a difference in health status?
Xia Y; Chen Y; Chen J; Gan Y; Su C; Zhang H; Long E; Yan F; Yang Y
Front Public Health; 2023; 11():1090623. PubMed ID: 37213608
[TBL] [Abstract][Full Text] [Related]
10. Measuring the indirect cost associated with advanced non-small cell lung cancer: a nationwide cross-sectional study in China.
Yang Y; Xia Y; Su C; Chen J; Long E; Zhang H; Gan Y; Yan F; Chen Y
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4205-4214. PubMed ID: 36056953
[TBL] [Abstract][Full Text] [Related]
11. Cost burden associated with advanced non-small cell lung cancer in Europe and influence of disease stage.
Wood R; Taylor-Stokes G
BMC Cancer; 2019 Mar; 19(1):214. PubMed ID: 30849964
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.
Gu X; Zhang Q; Chu YB; Zhao YY; Zhang YJ; Kuo D; Su B; Wu B
Lung Cancer; 2019 Jan; 127():84-89. PubMed ID: 30642557
[TBL] [Abstract][Full Text] [Related]
13. Economic outcomes of maintenance gefitinib for locally advanced/metastatic non-small-cell lung cancer with unknown EGFR mutations: a semi-Markov model analysis.
Zeng X; Li J; Peng L; Wang Y; Tan C; Chen G; Wan X; Lu Q; Yi L
PLoS One; 2014; 9(2):e88881. PubMed ID: 24586426
[TBL] [Abstract][Full Text] [Related]
14. Health Resource Utilization in Patients with Advanced Non-Small Cell Lung Cancer Receiving Chemotherapy in China.
Shi J; Zhu J
Clin Drug Investig; 2016 Jan; 36(1):77-86. PubMed ID: 26563152
[TBL] [Abstract][Full Text] [Related]
15. Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer.
Stokes ME; Muehlenbein CE; Marciniak MD; Faries DE; Motabar S; Gillespie TW; Lipscomb J; Knopf KB; Buesching DP
J Manag Care Pharm; 2009 Oct; 15(8):669-82. PubMed ID: 19803556
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.
Lu S; Ye M; Ding L; Tan F; Fu J; Wu B
Oncotarget; 2017 Feb; 8(6):9996-10006. PubMed ID: 28036283
[TBL] [Abstract][Full Text] [Related]
17. Gefitinib for advanced non-small cell lung cancer.
Sim EH; Yang IA; Wood-Baker R; Bowman RV; Fong KM
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD006847. PubMed ID: 29336009
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and adverse events of five targeted agents in the treatment of advanced or metastatic non-small-cell lung cancer: A network meta-analysis of nine eligible randomized controlled trials involving 5,059 patients.
Liu GF; Li XF; Yu SN; Miao YY; Zhang SH
J Cell Physiol; 2019 Apr; 234(4):3445-3457. PubMed ID: 30374969
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China.
Cai H; Zhang L; Li N; Chen S; Zheng B; Yang J; Weng L; Liu MB
Clin Ther; 2019 Feb; 41(2):280-290. PubMed ID: 30639208
[TBL] [Abstract][Full Text] [Related]
20. Gefitinib Versus Adjuvant Chemotherapy in Patients With Stage II-IIIA Non-Small-Cell Lung Cancer Harboring Positive EGFR Mutations: A Single-Center Retrospective Study.
Xie H; Wang H; Xu L; Li M; Peng Y; Cai X; Feng Z; Ren W; Peng Z
Clin Lung Cancer; 2018 Nov; 19(6):484-492. PubMed ID: 30369426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
